Article Sidebar

pdf
Date Published: 02/12/2025
Abstract Views: 0
Views pdf: 0
DOI: https://doi.org/10.51298/vmj.v556i1.16236
Issue
Vol. 556 No. 1 (2025)
Section
Các bài báo
How to Cite
Nguyễn, C. P., Vũ, T. T., Lại, T. Định, & Vũ, A. H. (2025). PRELIMINARY OUTCOMES OF TOTAL NEOADJUVANT THERAPY IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AT THE 103 MILITARY HOSPITAL. Vietnam Medical Journal, 556(1). https://doi.org/10.51298/vmj.v556i1.16236

PRELIMINARY OUTCOMES OF TOTAL NEOADJUVANT THERAPY IN PATIENTS WITH LOCALLY ADVANCED RECTAL CANCER AT THE 103 MILITARY HOSPITAL

Châu Phong Nguyễn, Thanh Tùng Vũ, Thị Định Lại, Anh Hải Vũ

Main Article Content

Abstract

This retrospective descriptive study included 30 patients with locally advanced rectal cancer (LARC) treated with total neoadjuvant therapy (TNT) at the 103 Military Hospital. The aim was to evaluate preliminary outcomes regarding treatment efficacy, toxicity. Endpoints included clinical complete response (cCR), pathological complete response (pCR), overall response rate (ORR), adverse events graded according to CTCAE v5.0, disease-free survival (DFS), and overall survival (OS). Initial findings showed that TNT achieved a high response rate, with cCR and pCR observed in 20% and 20% of patients, respectively. Toxicities were mainly mild to moderate and manageable. Conclusion: TNT demonstrated efficacy, safety, and feasibility in clinical practice in Vietnam. This approach may represent a promising strategy for the management of locally advanced rectal cancer, with the potential to improve prognosis and quality of life.

Article Details

Keywords

Rectal cancer, total neoadjuvant therapy, TNT, complete response

References

1. Giang DTT. Kết quả điều trị tân bổ trợ toàn bộ ở bệnh nhân ung thư trực tràng giai đoạn II, III tại Bệnh viện Trung ương Quân đội 108. Tạp chí Y Dược Lâm sàng 108. 2024;19(6).
2. Hoàng NH. Kết quả bước đầu hóa xạ trị đồng thời kết hợp hóa trị bổ trợ trước phẫu thuật bệnh nhân ung thư trực tràng giai đoạn II, III. Tạp chí Nghiên cứu Y học. 2024;179(6).
3. Amin MB, Edge SB, Greene FL, et al. AJCC Cancer Staging Manual. 8th ed. Springer; 2017.
4. Bahadoer RR, Dijkstra EA, van Etten B, et al. Short-course radiotherapy followed by chemotherapy before total mesorectal excision (RAPIDO): a randomised, open-label, phase 3 trial. Lancet Oncol. 2021;22(1):29-42.
5. Conroy T, Lamfichekh N, Etienne PL, et al. Neoadjuvant chemotherapy with FOLFIRINOX and preoperative chemoradiotherapy for patients with locally advanced rectal cancer (UNICANCER-PRODIGE 23): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2021; 22(5):702-715.
6. Garcia-Aguilar J, Patil S, Gollub MJ, et al. Organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy. J Clin Oncol. 2022;40(23):2546-2556.
7. Jin J, Tang Y, Hu C, et al. Multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR). J Clin Oncol. 2022;40(16): 1681-1692.
8. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2022;72(3): 209-249.